A Phase III, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy of AZD2171 (30 mg) in Combination with Gemcitabine and Cisplatin versus the Efficacy of Gemcitabine and Cisplatin alone in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.

Study identifier:D8480C00034

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase III, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy of AZD2171 (30 mg) in Combination with Gemcitabine and Cisplatin versus the Efficacy of Gemcitabine and Cisplatin alone in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria